# Sphere-9 PAF China Study

Study · id `cardio:ct-nct07789925` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07789925](<https://clinicaltrials.gov/study/NCT07789925>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07789925

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 180 participants.

## Technical summary

Registry record NCT07789925. Allocation not applicable; no masking; primary purpose treatment. Start 2026-09-02 (anticipated); primary completion 2028-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT07789925, source copy `cardio:ctgov-nct07789925-2026-08-27`, retrieved 2026-10-26)
- Planned start: 2026-09-02 (anticipated) (ClinicalTrials.gov record NCT07789925, source copy `cardio:ctgov-nct07789925-2026-08-27`, retrieved 2026-10-26)
- Primary completion: 2028-04 (anticipated) (ClinicalTrials.gov record NCT07789925, source copy `cardio:ctgov-nct07789925-2026-08-27`, retrieved 2026-10-26)
- Completion: 2028-04 (anticipated) (ClinicalTrials.gov record NCT07789925, source copy `cardio:ctgov-nct07789925-2026-08-27`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07789925, source copy `cardio:ctgov-nct07789925-2026-08-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07789925-2026-08-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sphere-9 PAF China Study
- Condition: Paroxysmal Atrial Fibrillation (PAF)
- Intervention (Device): Catheter ablation using Sphere-9™ Catheter and Affera™ Integrated Mapping and Ablation System
- Lead sponsor: Medtronic Cardiac Ablation Solutions
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Medtronic Cardiac Ablation Solutions (`cardio:org-medtronic-cardiac-ablation-solutions`)

## Provenance

Content hash: b7a8e417b953b3de9c8b8097b5c380d0bbae7331a036d0011a896d9f7c50e33b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
